Free Content

PLAIN LANGUAGE SUMMARIES

BAD guidelines for the management of HS (acne inversa) 2018

Linked article

Article first published online: 26 Apr 2019
DOI: 10.1111/bjd.17799

Comment on this article

Summary

Hidradenitis suppurativa (HS) is a long‐term skin condition causing multiple boils in skin creases such as the arm pits and groins. The boils are painful and produce pus, and permanent scarring occurs as the disease progresses. As a result, it has a large impact on quality of life. HS affects about 1 in 100 of the UK population and it tends to start in early adulthood. The British Association of Dermatologists commissioned a HS guideline development group composed of information specialists, a HS patient and carer, and UK clinicians including dermatologists, a dermatology nurse, plastic surgeon and general practitioner (GP). The group, based in the UK, were asked to produce treatment recommendations based on a systematic review of the evidence. The evidence was converted to recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Nearly 3000 evidence records were identified through database searches. Initial recommendations for HS management by GPs and hospital clinics include to provide a patient information leaflet, record baseline disease severity, measure pain and treat if needed, measure quality of life, record a count of skin lesions, and provide wound dressings if required. Patients should be screened for cardiovascular disease risk factors as well as for depression and anxiety. Patients should also be offered smoking cessation and weight management referral if relevant. A treatment ladder of medical therapy is recommended, starting with oral tetracyclines, then the combination of clindamycin and rifampicin, acitretin in men and non‐fertile women, dapsone and progressing to adalimumab injections if required. Surgical treatment with wide removal and a range of closure methods is placed towards the end of the medical treatment pathway, reflecting current UK practice and a relative lack of evidence. Future research recommendations and audit criteria are included.

Read moreRead more (PDF)

Share this article

0

Favourite

Comments

If you want to submit a letter for publication rather than comment on an article please submit through Scholar One: https://mc.manuscriptcentral.com/bjd

There are no comments for this article yet.

Recent Tweets

@BrJDermatol

18 Nov 2019

This #OpenAccess translational study suggests that #oxymatrine therapy is an alternative treatment for #psoriasis in the case of #acitretin allergy or adverse reactions: https://t.co/7AjdzEyZjZ https://t.co/BPZDOPS8hV

@BrJDermatol

15 Nov 2019

23F -> ED with 2/52 Hx of progressively worsening superficial erosions & blisters on feet. Rx of this condition well-controlled with zinc replacement since childhood. What is the diagnosis? What is the classic triad? https://t.co/CPWlw9dGXm #medderm #meded https://t.co/jimPLKbJPZ

@BrJDermatol

14 Nov 2019

What are the effects of psychosocial interventions for psoriasis patients and on patient-reported outcomes? https://t.co/envAXoD36N #psoriasis #psychosocial https://t.co/dVUDp4L7Hs

@BrJDermatol

13 Nov 2019

Find out how changing immunosuppressive treatment practices have impacted SCC and BCC cancer risk in organ transplant recipients at https://t.co/wlvY9C1BnB #SCC #BCC #organtransplant #epidemiology https://t.co/tofI5FYhdu

@BrJDermatol

13 Nov 2019

RT The British Association of Dermatologists @HealthySkin4All: We are very excited to be planning the launch of a new open access journal, for which we are now looking for an Editor-in-Chief. Full details and information on how to apply for this role can be found here: https://t.co/42Fego0m99 @BrJDermatol @ced_wiley https://t.co/RAtLL76qpd

@BrJDermatol

13 Nov 2019

RT Dr Katie Farquhar @katiefarquhar: Very interesting article looking at skin cancer trends in transplant recipients from @BrJDermatol https://t.co/ia0PTvQCx9

Close